摘要
局限性前列腺癌是临床上最为常见的疾病阶段,规范及优化疾病的诊疗有望提升患者的预后及生活质量。2022年7月,美国泌尿外科学会(American Urological Association,AUA)联合美国放射肿瘤学会(American Society for Radiation Oncology,ASTRO)共同发布了新一版临床局限性前列腺癌诊疗指南,主要包括风险评估、疾病分期、基于风险的处理、处理原则以及治疗后随访五个方面,本文对其推荐内容、强度和证据等级等进行归纳,并结合我国前列腺癌诊疗情况加以讨论和分析。
Standardizing and optimizing the diagnosis and treatment of the disease are expected to improve the prognosis and quality of life of patients.In July 2022,the American Urological Association(AUA)and the American Society for Radiation Oncology(ASTRO) jointly issued the new version of guideline for clinically localized prostate cancer,and the current guideline includes five aspects:risk assessment,staging,risk-based management,principles of management,and follow-up after treatment.This article summarized the guideline statements and their type and evidence strength,then we discussed and interpreted this guideline based on the diagnosis and treatment of prostate cancer in China.
作者
高旭
Gao Xu(Departnment of Urology,Changhai Hospital,Naval Medical University,Shanghai 200433,China)
出处
《泌尿外科杂志（电子版）》
2022年第4期24-30,共7页
Journal of Urology for Clinicians(Electronic Version)
基金
上海市优秀学术带头人项目(22XD1405000)
上海市申康临床科技创新项目(SHDC2021215)
国家重点研发计划(2020YFC2002704)
关键词
前列腺癌
临床局限性
指南
风险评估
疾病管理
Prostate cancer
Clinically localized
Guideline
Risk assessment
Disease management
